

RIBOMIC Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis

TOKYO, July 28, 2022 - RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the United States Patent and Trademark Office has issued Patent No.16/761,880 covering the composition of matter of RBM-010, the company's drug candidate in development to treat osteoarthritis (OA). RBM-010 has the potential to be a disease-modifying OA drug, with its potent and specific suppression of ADAMTS-5, an important risk factor for disease progression. The allowance of this patent in the U.S. strengthens company's intellectual property position, an important milestone for RBM-010's development and potential commercialization.

About Osteoarthritis and RBM-010

Osteoarthritis (OA) is a progressive disease of the joints characterized by degradation of articular cartilage, affecting more than 240 million adults in the world. There is no cure for OA. The currently available treatments are to help relieve the symptoms. ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs-5) is a key enzyme in the cartilage degradation and as such, is a relevant potential target for OA. RBM-010 is a novel oligonucleotide-based aptamer with potent anti-ADAMTS-5 activity.

ABOUT RIBOMIC

RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases.

See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

Administration Division

ir.inquiry@ribomic.com